Treatment of relapsed small-cell lung cancer - A focus on the evolving role of topotecan

Caio M Rocha Lima, Alberto Chiappori

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Despite the high response rates to chemotherapy, small-cell lung cancer (SCLC) is among the most lethal malignancies. Long-term survival is anecdotal for patients with extensive disease; 5-years survival is ≤5% for those with limited disease. All patients with extensive disease and most patients with limited disease will experience disease progression and become candidates for second-line therapy. Although a number of agents have demonstrated antitumor activity in relapsed SCLC, including paclitaxel, docetaxel, etoposide, cisplatin, and carboplatin, topotecan is the only single agent currently approved in the United States for the treatment of recurrent disease. Topotecan is a novel topoisomerase I inhibitor with established antitumor activity in recurrent SCLC and has a predictable, noncumulative toxicity profile. Furthermore, topotecan has been shown to provide symptom improvement in this predominantly palliative setting. Evidence also suggests that topotecan readily penetrates the blood-brain barrier and might be active in the relatively large subset of SCLC patients who experience brain metastases. This article reviews the clinical utility of topotecan in recurrent SCLC, including its efficacy, tolerability, and quality-of-life effect, when used as monotherapy and in novel combination regimens.

Original languageEnglish
Pages (from-to)229-236
Number of pages8
JournalLung Cancer
Volume40
Issue number3
DOIs
StatePublished - Jun 1 2003

Fingerprint

Topotecan
Small Cell Lung Carcinoma
docetaxel
Topoisomerase I Inhibitors
Therapeutics
Survival
Carboplatin
Etoposide
Paclitaxel
Blood-Brain Barrier
Cisplatin
Disease Progression
Quality of Life
Neoplasm Metastasis
Drug Therapy
Brain
Neoplasms

Keywords

  • Brain metastases
  • Chemotherapy
  • Recurrent disease
  • Second-line therapy
  • Small-cell lung cancer
  • Topoisomerase I
  • Topotecan

ASJC Scopus subject areas

  • Oncology

Cite this

Treatment of relapsed small-cell lung cancer - A focus on the evolving role of topotecan. / Lima, Caio M Rocha; Chiappori, Alberto.

In: Lung Cancer, Vol. 40, No. 3, 01.06.2003, p. 229-236.

Research output: Contribution to journalArticle

Lima, Caio M Rocha ; Chiappori, Alberto. / Treatment of relapsed small-cell lung cancer - A focus on the evolving role of topotecan. In: Lung Cancer. 2003 ; Vol. 40, No. 3. pp. 229-236.
@article{2b71dd7a9a544ca0883b4890a562c1a3,
title = "Treatment of relapsed small-cell lung cancer - A focus on the evolving role of topotecan",
abstract = "Despite the high response rates to chemotherapy, small-cell lung cancer (SCLC) is among the most lethal malignancies. Long-term survival is anecdotal for patients with extensive disease; 5-years survival is ≤5{\%} for those with limited disease. All patients with extensive disease and most patients with limited disease will experience disease progression and become candidates for second-line therapy. Although a number of agents have demonstrated antitumor activity in relapsed SCLC, including paclitaxel, docetaxel, etoposide, cisplatin, and carboplatin, topotecan is the only single agent currently approved in the United States for the treatment of recurrent disease. Topotecan is a novel topoisomerase I inhibitor with established antitumor activity in recurrent SCLC and has a predictable, noncumulative toxicity profile. Furthermore, topotecan has been shown to provide symptom improvement in this predominantly palliative setting. Evidence also suggests that topotecan readily penetrates the blood-brain barrier and might be active in the relatively large subset of SCLC patients who experience brain metastases. This article reviews the clinical utility of topotecan in recurrent SCLC, including its efficacy, tolerability, and quality-of-life effect, when used as monotherapy and in novel combination regimens.",
keywords = "Brain metastases, Chemotherapy, Recurrent disease, Second-line therapy, Small-cell lung cancer, Topoisomerase I, Topotecan",
author = "Lima, {Caio M Rocha} and Alberto Chiappori",
year = "2003",
month = "6",
day = "1",
doi = "10.1016/S0169-5002(03)00039-4",
language = "English",
volume = "40",
pages = "229--236",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Treatment of relapsed small-cell lung cancer - A focus on the evolving role of topotecan

AU - Lima, Caio M Rocha

AU - Chiappori, Alberto

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Despite the high response rates to chemotherapy, small-cell lung cancer (SCLC) is among the most lethal malignancies. Long-term survival is anecdotal for patients with extensive disease; 5-years survival is ≤5% for those with limited disease. All patients with extensive disease and most patients with limited disease will experience disease progression and become candidates for second-line therapy. Although a number of agents have demonstrated antitumor activity in relapsed SCLC, including paclitaxel, docetaxel, etoposide, cisplatin, and carboplatin, topotecan is the only single agent currently approved in the United States for the treatment of recurrent disease. Topotecan is a novel topoisomerase I inhibitor with established antitumor activity in recurrent SCLC and has a predictable, noncumulative toxicity profile. Furthermore, topotecan has been shown to provide symptom improvement in this predominantly palliative setting. Evidence also suggests that topotecan readily penetrates the blood-brain barrier and might be active in the relatively large subset of SCLC patients who experience brain metastases. This article reviews the clinical utility of topotecan in recurrent SCLC, including its efficacy, tolerability, and quality-of-life effect, when used as monotherapy and in novel combination regimens.

AB - Despite the high response rates to chemotherapy, small-cell lung cancer (SCLC) is among the most lethal malignancies. Long-term survival is anecdotal for patients with extensive disease; 5-years survival is ≤5% for those with limited disease. All patients with extensive disease and most patients with limited disease will experience disease progression and become candidates for second-line therapy. Although a number of agents have demonstrated antitumor activity in relapsed SCLC, including paclitaxel, docetaxel, etoposide, cisplatin, and carboplatin, topotecan is the only single agent currently approved in the United States for the treatment of recurrent disease. Topotecan is a novel topoisomerase I inhibitor with established antitumor activity in recurrent SCLC and has a predictable, noncumulative toxicity profile. Furthermore, topotecan has been shown to provide symptom improvement in this predominantly palliative setting. Evidence also suggests that topotecan readily penetrates the blood-brain barrier and might be active in the relatively large subset of SCLC patients who experience brain metastases. This article reviews the clinical utility of topotecan in recurrent SCLC, including its efficacy, tolerability, and quality-of-life effect, when used as monotherapy and in novel combination regimens.

KW - Brain metastases

KW - Chemotherapy

KW - Recurrent disease

KW - Second-line therapy

KW - Small-cell lung cancer

KW - Topoisomerase I

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0038360737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038360737&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(03)00039-4

DO - 10.1016/S0169-5002(03)00039-4

M3 - Article

C2 - 12781421

AN - SCOPUS:0038360737

VL - 40

SP - 229

EP - 236

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -